Clinical-stage biotechnology company Accro Bioscience Inc announced on Monday the closing of its USD50m Series C financing.
The round was led by OrbiMed, with participation from TCG Crossover, LAV, Cenova Capital, and existing investors Shenzhen Capital Group, and Oriza Holdings.
Accro Bioscience plans to use the proceeds from the financing to fund the Phase IIb clinical trial of AC-101, an RIPK2 inhibitor, for the treatment of Ulcerative Colitis (UC), and other novel therapeutic candidates for inflammatory and autoimmune diseases.
CellCarta partners with Sonic Healthcare to commercialise companion diagnostics through Lab Network
Accro Bioscience completes USD50m Series C financing
Mabwell's clinical trial application for 9MW5211 cleared by US FDA
Curocell secures full approval for RIMQARTO to enter CAR-T therapy market
HUTCHMED secures priority review for sovleplenib NDA in China
Circio partners with Acuitas to evaluate in vivo CAR-T cell therapy technology
Thermo Fisher Scientific unveils CHOvantage GS Kit to speed biologics development
Galapagos and Gilead expand collaboration to advance T cell engager programme
Aurinia Pharmaceuticals agrees to acquire Kezar Life Sciences
Thermo Fisher Scientific and SHL Medical launch integrated US drug-device manufacturing
Immunic granted European patent for vidofludimus calcium dosing regimens